J
Jan Sroubek
Publications - 7
Citations - 1051
Jan Sroubek is an academic researcher. The author has contributed to research in topics: Medicine & Temozolomide. The author has an hindex of 3, co-authored 4 publications receiving 808 citations.
Papers
More filters
Journal ArticleDOI
Maintenance therapy with tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial
Roger Stupp,Roger Stupp,S. Taillibert,Andrew A. Kanner,Santosh Kesari,David M. Steinberg,Steven A. Toms,Lynne P. Taylor,Frank S. Lieberman,Antonio Silvani,Karen Fink,Gene H. Barnett,Jay-Jiguang Zhu,John W. Henson,Herbert H. Engelhard,Thomas C. Chen,David Tran,Jan Sroubek,Nam D. Tran,Andreas F. Hottinger,Joseph Landolfi,Rajiv D. Desai,Manuela Caroli,Yvonne Kew,Jérôme Honnorat,Ahmed Idbaih,Eilon D. Kirson,Uri Weinberg,Yoram Palti,Monika E. Hegi,Zvi Ram +30 more
TL;DR: In this interim analysis of 315 patients with glioblastoma who had completed standard chemoradiation therapy, adding TTFields to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival.
Journal ArticleDOI
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Martin J.B. Taphoorn,Linda Dirven,Andrew A. Kanner,Gitit Lavy-Shahaf,Uri Weinberg,S. Taillibert,Steven A. Toms,Jérôme Honnorat,Thomas C. Chen,Jan Sroubek,Carlos A. David,Ahmed Idbaih,Jacob C. Easaw,Chae-Yong Kim,Jordi Bruna,Andreas F. Hottinger,Yvonne Kew,Patrick Roth,Rajiv D. Desai,John L. Villano,Eilon D. Kirson,Zvi Ram,Roger Stupp +22 more
TL;DR: The addition of TTFields to standard treatment with temozolomide for patients with glioblastoma results in improved survival without a negative influence on HRQoL except for more itchy skin, an expected consequence from the transducer arrays.
Journal ArticleDOI
Tumor Treating Fields (TTFields)—A Novel Cancer Treatment Modality: Translating Preclinical Evidence and Engineering Into a Survival Benefit with Delayed Decline in Quality of Life.
Roger Stupp,M. J. B. Taphoorn,L. Driven,S. Taillibert,J. Honnorat,Thomas C. Chen,Jan Sroubek,S. H. Paek,Jordi Bruna Escuder,Jacob C. Easaw,Carlos A. David,Chae-Yong Kim,Rajiv D. Desai,Alessandro Olivi,Yvonne Kew,Andreas F. Hottinger,Monika E. Hegi,Eilon D. Kirson,Gitit Lavy-Shahaf,Zvi Ram +19 more
Journal ArticleDOI
334PDTumor Treating Fields (TTFields) – A novel cancer treatment modality: Translating preclinical evidence and engineering into a survival benefit with delayed decline in quality of life
Roger Stupp,Martin J B Taphoorn,Linda Dirven,S. Taillibert,Jérôme Honnorat,Thomas C. Chen,Jan Sroubek,Sun Ha Paek,J. Bruna Escuder,Jacob C. Easaw,Carlos A. David,Chae-Yong Kim,Rajiv D. Desai,Yvonne Kew,Alessandro Olivi,Andreas F. Hottinger,Eilon D. Kirson,Gitit Lavy-Shahaf,Monika E. Hegi,Zvi Ram +19 more
Journal ArticleDOI
Eighteen years’ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
Jan Vymazal,Tomas Kazda,Tomas E. Novak,Petr Slanina,Jan Sroubek,Jan Klener,Tomáš Hrbáč,Martin Syrucek,Aaron Rulseh +8 more
TL;DR: In this article , low intensity electric fields (frequency 150-300 kHz) were used to disrupt cellular processes critical for cancer cell viability and tumor progression, and patients on TTFields therapy demonstrated improvements in PFS and OS relative to controls.